Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations
Andrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić · 2026
Read Therapeutic advances in spinal muscular atrophy: a review of clinical, safety, and economic considerations by Andrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13617402.txt.
Description
Andrej Belančić and co-authors checked the transformed treatment landscape of spinal muscular atrophy in 2026. The disease is a genetic mess in which a missing survival motor neuron protein, caused by mutations in the SMN1 gene, destroys the motor neurons of the spinal cord. Within a few years, three approved disease-modifying treatments have changed its course: an injected antisense drug, a one-time gene treatment, and a daily oral drug.
The review summarizes trial efficacy and real-world effectiveness for all three, finding major gains in survival, motor milestones, and quality of life, strongest when treatment starts early. Safety data from trials and post-marketing surveillance show manageable side effects. The harder chapter is economics: prices are high and cost-effectiveness strains standard thresholds, though context matters. A section surveys the workflow of next-generation treatments aiming at the missing protein and independent targets such as muscle itself.
Catalog record
| CREATOR | Andrej Belančić, Elvira Meni Maria Gkrinia, Yun Wah Lam, Dinko Vitezić |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 58 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |